© 2022 MJH Life Sciences™ and Contemporary Pediatrics. All rights reserved.
Respiratory
The Role of the Healthcare Provider Community in Increasing Public Awareness of RSV in All Infants
April 02, 2022
Scott Kober sits down with Dr. Joseph Domachowske, Professor of Pediatrics, Professor of Microbiology and Immunology, and Director of the Global Maternal-Child and Pediatric Health Program at the SUNY Upstate Medical University.
Is hydrocortisone an effective way to improve bronchopulmonary dysplasia outcomes?
March 30, 2022
An investigation examines whether a treatment of hydrocortisone could lead to a reduction in moderate to severe bronchopulmonary dysplasia and neurodevelopmental outcomes at age 2 years.
Do we take RSV disease seriously enough?
March 28, 2022
What the HCP community can do to change our approach
What influences thirdhand smoke exposure
February 17, 2022
Thirdhand smoke exposure poses a health threat to children. New research examines the factors that may lead to some children having more exposure than others.
Comparing LABA plus inhaled corticosteroids to inhaled corticosteroids only for treating prematurity-associated lung disease
December 15, 2021
Decreased lung function may be a result of a preterm delivery. Does treatment with long-acting β2 agonists (LABA) plus inhaled corticosteroids perform better than just inhaled corticosteroids to improve lung function in affected children?
Examining the efficacy of dupilumab for uncontrolled asthma in kids 6-11
December 14, 2021
Used to treat asthma in adolescents and adults, a clinical trial examines whether it would be effective in treating uncontrolled asthma in younger children.
Utilizing peer leaders to improve asthma management in teens living in urban areas
December 09, 2021
In spite of the availability of effective treatments, asthma is not always well controlled among teenagers. An investigation examines whether using peers to helm education efforts can lead to improved outcomes.
Examining the seasonal shift of RSV
December 07, 2021
The jury is out on whether testing or exposure better explains the unseasonable surge of respiratory syncytial virus.
Priority review of VAXNEUVANCE™ for kids 6 weeks to 17 years accepted by FDA
December 02, 2021
The US Food and Drug Administration has accepted a Priority Review of the pneumococcal 15-valent conjugate vaccine VAXNEUVANCE™ in children aged 17 years and younger.
Study into long-term outcomes of COVID-19 in kids launched
November 18, 2021
The National Institutes of Health announced the launch of a long-term study into the long ranging outcomes of recovering from COVID-19 in children, adolescents, and young adults.